ImmunityBio Inc (IBRX)
8.12
+0.06
(+0.74%)
USD |
NASDAQ |
May 10, 16:00
8.03
-0.09
(-1.11%)
After-Hours: 20:00
ImmunityBio Total Liabilities (Quarterly): 1.090B for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.090B |
| September 30, 2023 | 843.06M |
| June 30, 2023 | 936.41M |
| March 31, 2023 | 875.12M |
| December 31, 2022 | 812.18M |
| September 30, 2022 | 782.02M |
| June 30, 2022 | 739.69M |
| Date | Value |
|---|---|
| March 31, 2022 | 727.14M |
| December 31, 2021 | 712.82M |
| September 30, 2021 | 404.36M |
| June 30, 2021 | 404.89M |
| March 31, 2021 | 394.76M |
| December 31, 2020 | 339.87M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
339.87M
Minimum
Dec 2020
1.090B
Maximum
Dec 2023
697.13M
Average
739.69M
Median
Jun 2022
Total Liabilities (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | 103.53M |
| iBio Inc | 24.82M |
| Lixte Biotechnology Holdings Inc | 0.3139M |
| Abeona Therapeutics Inc | 49.18M |
| Chromocell Therapeutics Corp | 5.927M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 504.45M |
| Shareholders Equity (Quarterly) | -586.99M |
| Debt to Equity Ratio | -1.161 |
| Current Ratio | 5.046 |
| Net Debt Paydown Yield | -0.12% |